Last updated: May 31, 2026
IOPAMIDOL-370 (iodinated contrast media, 370 mgI/mL class) is a mature US and ex-US radiology commodity with pricing discipline driven by hospital contracting, group purchasing organizations (GPOs), and payer-style procurement. Financial trajectory is primarily determined by (1) conversion of procedure volumes from competitors within the low-osmolality iohexol/iopamidol segment, (2) mix shift between 370 and adjacent concentrations (typically 300 and 350) and between ready-to-use vials vs larger packaging, and (3) episodic supply constraints that move short-term share. Patent and exclusivity risks are comparatively low at the product-label level because the active substance is long off-patent; the binding economics sit in label-level formulations, packaging, and abbreviated new drug submissions that preserve generic entry.
What drives IOPAMIDOL-370 market share and pricing in the US?
Primary drivers are procurement mechanics, substitution rates, and medical-use inertia rather than incremental clinical differentiation. In iodinated contrast media, hospitals buy based on formulary placement, contract pricing, and inventory cadence. Even where multiple products are therapeutically interchangeable, procurement often lags clinical switching because clinicians are habituated to specific product portfolios stocked by radiology departments.
Procurement structure: how contracts shape realized price
- GPO and IDN contracting: Most US realized pricing is set through GPO-negotiated tiers and IDN (integrated delivery network) contracts.
- Multi-source pressure: Low-osmolality iodinated contrast media are typically multi-source, pushing price increases down and shifting revenue via share and volume.
- Packaging economics: Larger bottle sizes, vials vs prefilled sets, and distribution channel packaging influence unit economics.
Clinical switching: what moves volume between iodinated agents
- Procedure mix: CT volume growth raises contrast utilization.
- Contrast protocol norms: Many facilities use fixed dosing protocols in mL/kg, but concentration selection (e.g., 370 vs 350/300) is driven by institutional protocol and scanner workflow.
- Adverse-event and departmental policy constraints: Policies around “preferred product” after reactions can reduce substitution elasticity.
How is IOPAMIDOL-370 trending commercially by revenue and volume?
IOPAMIDOL-370 typically follows a mature-market profile: steady volume growth with moderated unit-price growth and periodic share swings from contracting or supply disruptions. The financial trajectory generally looks like:
- Revenue growth: Driven by procedure volume and share retention under contract.
- Margin compression: Persisting due to multi-source competition and normalization of pricing.
- Share volatility: Higher around contract renewals, tender cycles, and any manufacturing or logistics constraints.
Hospital and distributor channel impacts
- Distributor re-order cycles: Short lead times can stabilize near-term volumes; long lead times can shift short-term volume to whatever is available under contract.
- Inventory management: Radiology groups often keep small safety stock, so supply tightness can cause short-term substitution to alternative agents.
Commercial metrics that matter for financial trajectory
- Net sales per unit and per mL rather than headline bottle price, because mix between concentrations and pack sizes can shift realized revenue.
- Contract coverage rate: % of target hospitals within the relevant GPO/IDN contracts.
- Share by procedure: CT contrast use split among agent families (iohexol, iopamidol, ioversol, etc.).
What is the competitive landscape for IOPAMIDOL-370 (iohexol, iopamidol, ioversol)?
IOPAMIDOL-370 competes in the broader iodinated contrast media market, where the most common direct substitution set includes:
- Iohexol (low-osmolality iodinated contrast): Often used as a formulary alternative.
- Iopamidol at other concentrations: Same active, different mgI/mL.
- Ioversol and similar nonionic contrast agents: Common contract alternatives in CT protocols.
How brands and generics compete
- Multi-source generic presence is the norm at the active-ingredient level for iopamidol formulations.
- Brand differentiation is limited to packaging, distribution channel reliability, and sometimes device/format specific to labeling.
What typically wins tenders
- Lowest net price under contract after rebates and logistics terms.
- Demonstrated supply reliability and consistent lot acceptance performance.
- Familiarity of clinicians and procurement committees with the product and interchangeability.
When does IOPAMIDOL-370 lose exclusivity, and what does that mean for revenue risk?
At the active ingredient level, iopamidol and its nonionic iodinated contrast formats are generally mature, with limited remaining exclusivity for the base compound in most major jurisdictions. For revenue risk, the practical question is less “loss of exclusivity for the active ingredient” and more “what formulation/packaging/IP is still enforceable that could block generic substitution or label-level entry.”
Revenue sensitivity to label-level exclusivity
- Short-term protection can exist for specific packaging formats, labeling combinations, or manufacturing process patents.
- When those end or are designed around, generics typically capture share quickly because the therapeutic class is interchangeable.
What patents protect IOPAMIDOL-370 formulations and packaging?
Protection, where it exists in the real economy, is usually on formulation-specific manufacturing details, container/closure, and packaging format rather than the core chemistry. Patent estates for mature contrast agents tend to be:
- Process-related (manufacturing controls or impurity profiles).
- Product-by-pack (specific bottle sizes, container systems).
- Composition of matter refinements (less common for long-standing actives).
How to assess “IP that matters” for IOPAMIDOL-370
For business decisions, the enforceable risk typically comes from:
- Outstanding patents listed in regulatory patent databases tied to the exact marketed presentation (dose, concentration, container type).
- Any active Orange Book listings that are not yet expired.
- Any ongoing litigation tied to those listings.
What is the Orange Book status of IOPAMIDOL-370?
The active-ingredient class is broadly off-patent in the US, with typical Orange Book exposure limited to remaining label-level patents or packaging-specific listings. For investors and litigators, the Orange Book assessment must be presentation-specific (product name, concentration, dosage form, and manufacturer/holder alignment) because coverage is tied to NDA/BLA listings and listed patents per presentation.
Does IOPAMIDOL-370 face Paragraph IV challenges or generic entry risk?
Paragraph IV risk exists at the NDA product and presentation level when a reference-listed product has enforceable, unexpired patents. In mature iodinated contrast categories, generic competition is often already established, so incremental risk usually comes from:
- New entrants launching a “next best” supply contract position.
- Entry against patents that were previously controlling for specific pack sizes or label presentations.
- Design-around of method/process claims.
What patent litigation affects IOPAMIDOL-370 market dynamics?
In mature commodity classes, litigation is most likely to influence:
- Timing of specific generic launches against listed patents.
- Settlement-driven “at-risk but delayed” entry that temporarily preserves share for incumbents.
- Inventory and purchasing decisions during the uncertainty window.
For a given product’s financial trajectory, the key is whether litigation changes launch timing for a major competitor, not whether litigation happens in general.
How does IOPAMIDOL-370 compare with iodinated contrast peers on market economics?
The market economics across iodinated contrast media are structurally similar:
- Multiple approvals and suppliers.
- Procurement-based pricing.
- Volume growth linked to CT utilization and protocol practices.
Key economic comparison dimensions
- Net price index: contract-driven, frequently compressed.
- Supply reliability: can override pure price in practice for hospitals during constraints.
- Mix between concentrations: 370 mgI/mL competes with nearby concentrations based on dosing workflow.
What manufacturing and supply-chain risks affect IOPAMIDOL-370 financial performance?
IODINATED contrast media supply depends on:
- Specialty chemical inputs and iodine sourcing.
- Sterile manufacturing capacity.
- Compliance and lot release execution.
How supply disruptions translate into financial outcomes
- Short-term revenue upside for the available supplier under contract preference.
- Substitution ripple effects can persist post-normalization if procurement locks in a new preferred SKU.
How could new biosimilars or biologics affect IOPAMIDOL-370?
Not directly. IOPAMIDOL-370 is a small-molecule contrast agent and competes within radiology contrast media procurement, not in biologics ecosystems.
What dosing formats and presentations matter most for sales trajectory?
Even within 370 mgI/mL, unit economics vary with:
- Container size (mL per vial/bottle).
- Number of units per package.
- Distribution channel packaging and hospital receiving preferences.
Presentation-level switching
Hospitals frequently keep protocols tied to bottle sizes to reduce wastage and ensure standardized dosing. When a competitor introduces a pack that reduces waste or matches inventory flow, substitution can accelerate.
What licensing or settlement agreements could shift the competitive set?
In mature contrast-agent categories, licensing or settlements can still matter if they:
- Enable a specific entrant to launch earlier than would be allowed under patent exclusivity.
- Swap market access rights in exchange for non-infringement or delayed entry.
- Resolve disputes for one or more presentations rather than the entire class.
The financial impact is usually concentrated in a narrow window around contract renewals and launch timing.
Commercial outlook: what is the most likely financial trajectory for IOPAMIDOL-370?
Base case: Stable-to-moderate revenue growth with continued net price pressure and share competition driven by procurement cycles.
Upside scenario: Share gains from contract awards, improved supply reliability, and favorable protocol adoption.
Downside scenario: Contract loss, sustained net price compression from aggressive multi-source competition, or loss of preferred status after procurement re-bids.
Key Takeaways
- IOPAMIDOL-370 is governed by mature-market dynamics: hospital contracting, substitution elasticity, and procedural volume.
- Financial trajectory typically reflects steady use growth offset by net price discipline and margin compression from multi-source competition.
- Patent risk is mostly presentation-level (formulation/packaging/manufacturing and Orange Book-listed patents), with active ingredient exclusivity largely not the primary determinant.
- Supply reliability can cause short-term revenue swings and longer-lasting procurement shifts.
- The decisive market lever is realized net sales via contract coverage and presentation mix, not list pricing.
FAQs
- How do GPO contract tiers influence IOPAMIDOL-370 net pricing versus list price?
- What presentation-level factors (vial size, pack format) most drive switching between 370 mgI/mL contrast products?
- How do Orange Book-listed patents tied to specific iopamidol presentations affect generic launch timing?
- What supply-chain indicators predict short-term shortages and substitution risk for iodinated contrast media?
- How does CT volume growth translate into iodinated contrast utilization and IOPAMIDOL-370 demand?
References
- (No citations available from the provided prompt.)
